DE602004019063D1 - Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferi - Google Patents

Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferi

Info

Publication number
DE602004019063D1
DE602004019063D1 DE602004019063T DE602004019063T DE602004019063D1 DE 602004019063 D1 DE602004019063 D1 DE 602004019063D1 DE 602004019063 T DE602004019063 T DE 602004019063T DE 602004019063 T DE602004019063 T DE 602004019063T DE 602004019063 D1 DE602004019063 D1 DE 602004019063D1
Authority
DE
Germany
Prior art keywords
containing compounds
subject
cholesterol containing
immunogen against
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004019063T
Other languages
English (en)
Inventor
Gil Ben-Menachem
Joanna Kubler-Kielb
Rachel Schneerson
John B Robbins
Vince Pozsgay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE602004019063D1 publication Critical patent/DE602004019063D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE602004019063T 2003-04-02 2004-04-02 Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferi Expired - Lifetime DE602004019063D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46018403P 2003-04-02 2003-04-02
PCT/US2004/010007 WO2004089969A2 (en) 2003-04-02 2004-04-02 Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi

Publications (1)

Publication Number Publication Date
DE602004019063D1 true DE602004019063D1 (de) 2009-03-05

Family

ID=33159740

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004019063T Expired - Lifetime DE602004019063D1 (de) 2003-04-02 2004-04-02 Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferi

Country Status (11)

Country Link
US (2) US7666846B2 (de)
EP (2) EP2030979A1 (de)
JP (1) JP2006522808A (de)
CN (2) CN100351265C (de)
AT (1) ATE420887T1 (de)
AU (1) AU2004228631B2 (de)
CA (1) CA2521120A1 (de)
DE (1) DE602004019063D1 (de)
ES (1) ES2320998T3 (de)
RU (1) RU2385323C2 (de)
WO (1) WO2004089969A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019131A2 (en) * 2006-08-04 2008-02-14 The Trustees Of The University Of Pennsylvania Methods and compositions for treating ige-mediated diseases
US8286068B2 (en) * 2008-04-25 2012-10-09 Microsoft Corporation Linking digital and paper documents
KR102085465B1 (ko) 2010-05-14 2020-03-05 박스알타 인코퍼레이티드 키메라 ｏｓｐａ 유전자, 단백질 및 이의 사용 방법
US20230338495A1 (en) * 2020-08-19 2023-10-26 Vitruviae LLC Vaccine Compositions and Antibodies For Lyme Disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US3966918A (en) * 1973-12-12 1976-06-29 Nippon Shinyaku Co., Ltd. Method of preparing aqueous solutions of sterol glycosides and their ester derivatives
GB1468473A (en) * 1974-08-14 1977-03-30 Nippon Shinyaku Co Ltd Method for the preparation of steryl beta-d-glucoside palmitates
JPS51139613A (en) * 1975-05-24 1976-12-02 Nippon Shinyaku Co Ltd An absorbable non-crystalline sterol glycoside monopalmitate ester and a method for preparing its pharmaceutical
US4254111A (en) * 1978-07-05 1981-03-03 Roecar Holdings (Netherlands Antilles) Nv Sterolin products
US4189471A (en) * 1978-07-11 1980-02-19 Merck & Co., Inc. Immunologic glycolipid adjuvants
US4229441A (en) * 1978-12-01 1980-10-21 Merck & Co., Inc. Immunologic adjuvant
US4259324A (en) * 1979-07-31 1981-03-31 Merck & Co., Inc. Immunologic adjuvant thio glycoside compounds and compositions
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4721617A (en) * 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US5185154A (en) 1989-02-02 1993-02-09 Liposome Technology, Inc. Method for instant preparation of a drug containing large unilamellar vesicles
JP2779774B2 (ja) 1994-08-31 1998-07-23 日清製油株式会社 ステリルグリコシドの選択的アシル化方法

Also Published As

Publication number Publication date
ES2320998T3 (es) 2009-06-01
ATE420887T1 (de) 2009-01-15
CN101195649A (zh) 2008-06-11
WO2004089969A2 (en) 2004-10-21
CN100351265C (zh) 2007-11-28
RU2005133709A (ru) 2006-05-10
WO2004089969A3 (en) 2004-12-16
US20060204515A1 (en) 2006-09-14
US20100062023A1 (en) 2010-03-11
RU2385323C2 (ru) 2010-03-27
AU2004228631B2 (en) 2010-12-02
CN1771256A (zh) 2006-05-10
EP2030979A1 (de) 2009-03-04
EP1613641B1 (de) 2009-01-14
CA2521120A1 (en) 2004-10-21
JP2006522808A (ja) 2006-10-05
US7666846B2 (en) 2010-02-23
AU2004228631A1 (en) 2004-10-21
EP1613641A2 (de) 2006-01-11

Similar Documents

Publication Publication Date Title
ATE269056T1 (de) Hochwirksame dihydroergotaminhaltige arzneizusammensetzungen
DE69127470D1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
DE60120936D1 (de) Behandlung von atemerkrankungen
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BRPI0117180B8 (pt) composição farmacêutica em uma forma de unidade sólida de dosagem para a administração oral a um ser humano ou animal inferior
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
RU2005105576A (ru) Производные плевромутилина в качестве противомикроюных средств
BRPI0518781A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto
DE69231298T2 (de) Substituierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen und Anwendungsmethoden
AR008387A1 (es) Nuevas 5-fenoxialquil-tiazolidin-2,4-dionas, procedimientos para obtenerlas, nuevos compuestos intermedios de estos procedimientos ycomposiciones farmaceuticas que contienen las nuevas 5-fenoxialquil-tiazolidin- 2,4-dionas
DK0920865T3 (da) Farmaceutiske sammensætninger indeholdende norastemizol
ATE290858T1 (de) N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
ATE420887T1 (de) Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferi
DE69414354T2 (de) Polyzyklische aromatische Verbindungen, sie enthaltende pharmazeutische und kosmetische Zusammensetzungen und deren Verwendungen
FR2680172B1 (fr) Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
Rasmussen et al. Intraarticular glucocorticoid, morphine and bupivacaine reduces pain and convalescence after arthroscopic ankle surgery: a randomized study of 36 patients
Suksathien et al. Clinical study of a new design multifunction dynamic external fixator system for open tibial fracture
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
DE69403110D1 (de) Zyklische Angiopeptin Derivate, deren Herstellung und pharmazeutische Zusammensetzungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition